We are live on ! Find out more
LGM

Logos Global Management Portfolio holdings

AUM $2B
1-Year Est. Return 444.09%
This Fund
S&P 500
This Quarter Est. Return
-13.75%
1 Year Est. Return
+444.09%
3 Year Est. Return
+1,593.63%
5 Year Est. Return
+2,146.66%
10 Year Est. Return
–
AUM
$1.02B
AUM Growth
-$142M
Cap. Flow
+$82.3M
Cap. Flow %
8.03%
Top 10 Hldgs %
68.99%
Holding
83
New
24
Increased
8
Reduced
9
Closed
30

Top Buys

Rank Stock Value
1
DSGN icon
Design Therapeutics
DSGN
+$92.2M
2
TIL icon
Instil Bio
TIL
+$47.4M
3
EWTX icon
Edgewise Therapeutics
EWTX
+$34.3M
4
DYN icon
Dyne Therapeutics
DYN
+$31M
5
BCYC
Bicycle Therapeutics
BCYC
+$20.6M

Top Sells

Rank Stock Value
1
TGTX icon
TG Therapeutics
TGTX
+$44.2M
2
KROS icon
Keros Therapeutics
KROS
+$31.7M
3
NKTX icon
Nkarta
NKTX
+$20.1M
4
APLS
Apellis Pharmaceuticals
APLS
+$17.2M
5
RNAM
Avidity Biosciences
RNAM
+$17.1M

Sector Composition

Rank Sector Weight
1 Healthcare 99.46%
2 Financials 0.5%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ISEE
26
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$7.42M 0.72%
+1,200,000
New +$7.28M
KNSA icon
27
Kiniksa Pharmaceuticals
KNSA
$4.89B
$7.4M 0.72%
+400,000
New +$8.18M
LABP
28
DELISTED
Landos Biopharma, Inc. Common Stock
LABP
$7.07M 0.69%
+73,400
New +$9.58M
PMVP icon
29
PMV Pharmaceuticals
PMVP
$62.9M
$6.58M 0.64%
200,000
+100,000
+100% +$3.94M
HARP
30
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
$6.28M 0.61%
+30,000
New +$6.01M
SPRY icon
31
ARS Pharmaceuticals
SPRY
$572M
$5.45M 0.53%
125,000
-175,000
-58% -$8.28M
PNT
32
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
$5.25M 0.51%
500,000
– –
BOLT icon
33
Bolt Biotherapeutics
BOLT
$7.63M
$4.94M 0.48%
+7,500
New +$4.88M
KZR
34
DELISTED
Kezar Life Sciences
KZR
$4.77M 0.47%
+80,000
New +$4.68M
ANNX icon
35
Annexon
ANNX
$841M
$4.44M 0.43%
159,622
– –
VIRX
36
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$4.35M 0.42%
+470,000
New +$4.9M
CCCC icon
37
C4 Therapeutics
CCCC
$397M
$4.18M 0.41%
112,928
-365,000
-76% -$14.5M
LRMR icon
38
Larimar Therapeutics
LRMR
$398M
$3.36M 0.33%
230,000
-485,000
-68% -$8.81M
OBIO icon
39
Orchestra BioMed
OBIO
$229M
$3.36M 0.33%
300,000
– –
HRMY icon
40
Harmony Biosciences
HRMY
$2.08B
$3.3M 0.32%
100,000
– –
RACB
41
DELISTED
Research Alliance Corp. II Class A Common Stock
RACB
$3.08M 0.3%
+300,000
New +$3.07M
LHDX
42
DELISTED
Lucira Health, Inc. Common Stock
LHDX
$3.02M 0.3%
+250,000
New +$4.96M
PRDS
43
DELISTED
Pardes Biosciences, Inc. Common Stock
PRDS
$2.99M 0.29%
+300,000
New +$3.1M
DCPH
44
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$2.78M 0.27%
+62,000
New +$2.89M
CNTB
45
Connect Biopharma Holdings
CNTB
$132M
$2.77M 0.27%
+150,000
New +$2.55M
EAR
46
DELISTED
Eargo, Inc. Common Stock
EAR
$2.5M 0.24%
2,500
– –
ELDN icon
47
Eledon Pharmaceuticals
ELDN
$276M
$2.4M 0.23%
224,071
– –
TNGX icon
48
Tango Therapeutics
TNGX
$4.35B
$2.22M 0.22%
200,000
– –
PASG icon
49
Passage Bio
PASG
$14.8M
$2.19M 0.21%
6,251
-10,971
-64% -$4.68M
ARYD
50
DELISTED
ARYA Sciences Acquisition Corp IV Class A Odinary Shares
ARYD
$2.1M 0.2%
+200,000
New +$2.16M
1
2
3 4

Similar funds

MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
LBC
Lowe Brockenbrough & Co Richmond, Virginia $2.01B AUM 22.05% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BGM
Burkehill Global Management New York $2.02B AUM 85.32% 1-Year Est. Return
SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
AF
Alerus Financial Grand Forks, North Dakota $2.02B AUM 26.03% 1-Year Est. Return

Logos Global Management's Q1 2021 Portfolio in Review

As of Q1 2021, Logos Global Management held 83 positions worth $1.02B, down 12% from $1.17B the previous quarter. Its ten largest holdings account for 69% of the portfolio.

Logos Global Management deployed $82.3M of net new capital in Q1 2021, opening 24 new positions and adding to 8 existing holdings. Its largest new stake was Design Therapeutics: 2,732,501 shares worth $81.7M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 97% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Nkarta, an estimated $20.1M trimmed.

  • Logos Global Management's largest Q1 2021 buy was Design Therapeutics: 2,732,501 shares worth $81.7M.
  • Logos Global Management added most to Dyne Therapeutics in Q1 2021, an estimated $31M increase.
  • Logos Global Management's biggest Q1 2021 reduction was Nkarta, cutting an estimated $20.1M.
  • Logos Global Management fully exited TG Therapeutics in Q1 2021, selling an estimated $44.2M.
  • Logos Global Management's ten largest holdings make up 69% of its $1.02B portfolio in Q1 2021.
  • Logos Global Management opened 24 new positions and closed 30 in Q1 2021.
  • Logos Global Management's portfolio value fell 12% quarter-over-quarter to $1.02B.

Based on Logos Global Management's 13F filing for Q1 2021, filed 17 May 2021.